JenaValve, Insightec, Neukio Biotherapeutics
UK-based Apricity raises €17 million for its virtual fertility clinic and embarks on European expansion
Healthtech startup Apricity has just announced the raise of €17 million in a Series B round to expand its virtual fertility clinic solution across Europe. The funding was led by MTIP, the Swiss healthtech investor, with participation from Barcelona-based specialist consumer fund Iris Ventures. The UK-based company is aiming to become Europe’s leading fertility player with its solution that enhances patient experiences.
Launched in 2018 in the UK, Apricity is taking a fresh approach to reproductive health, blending personal, patient-centric fertility care with cutting-edge tech. In doing so, the startup aims to help people increase their chances of conception without the need to travel to a clinic, all while offering a smoother patient experience. The virtual clinic assists with every step of the fertility treatment journey and provides continuous, personalized support through its app. Apricity has pioneered new technologies to transform fertility care, developing first-of-its-kind AI algorithms that identify the most suitable fertility treatment for patients and then determine the best embryo for selection through 3D reconstruction. Apricity is the first company to develop 3D reconstruction technology for embryos to assist in fertility treatments.
UK-based Apricity raises €17 million for its virtual fertility clinic and embarks on European expansion | EU-Startups
Healthtech startup Apricity has just secured €17million to grow its virtual fertility clinic. The UK-based company is aiming to become Europe’s leading
JenaValve Raises $100M in Series C Funding
JenaValve, an Irvine, CA-based developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, raised $100M in Series C funding.
The round was led by Bain Capital Life Sciences with participation from existing investors Andera Partners, Valiance Advisors, Gimv, Cormorant Asset Management, RMM, and Venture Incubator. New investors joining the syndicate included Pictet Alternative Advisors SA, Qatar Investment Authority (QIA), Innovatus Capital Partners, and Peijia Medical Limited.
The company intends to use the funds to complete its investigational device exemption (IDE) premarket approval (PMA) study to obtain FDA approval for its Trilogy Heart Valve System, a treatment for high surgical risk patients with symptomatic, severe aortic regurgitation (AR). In addition, JenaValve will use the proceeds to bolster its real-world data development initiatives in Europe, as well as to expand its worldwide manufacturing capabilities.
Led by CEO John Kilcoyne, JenaValve Technology is a medical device company focused on the design, development, and commercialization of innovative transcatheter heart valve solutions for the treatment of patients suffering from heart valve disease.
JenaValve Raises $100M in Series C Funding - FinSMEs
JenaValve, a Irvine, CA-based developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, raised $100M in Series C funding
Insightec Receives up to $200M Financing
Insightec, a Haifa, Israel and Miami, FL-based healthcare company dedicated to using acoustic energy to transform patient care, signed a credit facility for up to $200 million with affiliates of existing shareholders Perceptive Advisors and Community Fund.
The financing has provided Insightec with $100 million at closing, with an additional $100 million of financing potentially available in tranches through 2024. The credit facility is interest-only for five years and matures on August 31, 2027.
The company intends to use the funds to drive adoption of incisionless neurosurgery to treat patients with Essential Tremor and Parkinson’s Disease, while continuing to advance innovation and clinical trials for expanded applications of its technology in neuro-oncology and other neurological conditions.
Led by CEO Maurice R. Ferré, Insightec leverages the Exablate Neuro platform to provide sound waves, guided by MRI, to provide tremor treatment to patients with medication-refractory Essential Tremor and Parkinson’s Disease. Research for future applications in the neuroscience space is underway in partnership with leading academic and medical institutions.
Insightec Receives up to $200M Financing - FinSMEs
Insightec, a Haifa, Israel and Miami, FL-based healthcare company dedicated to using acoustic energy to transform patient care, signed a credit facility for up to $200 million with affiliates of existing shareholders Perceptive Advisors and Community Fund
Neukio Biotherapeutics Closes $50M Series A-1 Financing
Neukio Biotherapeutics, a Chinese company committed to developing cell therapy products, raised $50M in Series A-1 funding.
The round was led by CD Capital, with participation from Alwin Capital, Surplus Capital, Lilly Asia Ventures, Sherpa Healthcare Partners and IDG Capital.
The company, founded at the Simbay Park in Shanghai Pilot Free Trade Zone (China) in June 2021, intends to use the funds to accelerate the preclinical and clinical validation of induced pluripotent stem cell (iPSC)-derived off-the-shelf CAR-NK cell therapy products, and support team recruitment and expansion.
Led by CEO Dr. Richard Liqun Wang, Neukio Biotherapeutics is a biotherapeutic company focusing on the development and commercialization of immune cell therapy. Its management team has established an iPSC-CAR-NK-based pipeline development strategy, aiming to launch allogenic off-the-shelf cell therapy products that can be produced in scale for treating solid tumors. The company focuses on both in-house R&D to provide valuable clinical solutions for cancer patients worldwide.
Since its establishment just over one year ago, Neukio has made remarkable progress in talent recruitment, facility construction, R&D pipeline advancement and quality management system establishment, exceeding all expectations.
Neukio Biotherapeutics Closes $50M Series A-1 Financing
Neukio Biotherapeutics, a Chinese company committed to developing cell therapy products, raised $50M in Series A-1 funding
Cantos Venture Raises $50M for Third Fund
Cantos Venture, a San Francisco, CA-based venture capital firm, raised $50M for their third fund.
The vehicle is focused on pre-seed and seed-stage investments in deeply technical climate, TechBio, aerospace, and next-gen computing startups.
Led by Ian Rountree, Founder & GP, Cantos Ventures invests in what they call “near frontier” startups, which have the potential to mitigate climate change, disease, armed conflict, poverty, and existential risk on a global scale.
The firm has invested in over 50 deep tech startups to-date.
Notable investments include:
Astranis, which is making satellite connectivity cheaper for billions without internet Atom Computing, a quantum computing company Faeth Therapeutics, a biotech using nutrition to fight cancer Fleetzero, which is decarbonizing ocean freight with electric ships Humane, which aims to transform how we interact with technology in the real world Mission Barns, an an alternative meat company that uses cultivated fat technology Radiant, which is building zero-emission portable fission reactors Skyryse, which makes air travel safer and more accessible through avionics innovation Solugen, which turns sugar into chemicals, replacing petroleum Twelve, which transforms CO2 into fossil-free essential chemicals Venus Aerospace, a hypersonic defense and transportation startup
